.M., Composto, R.J., Freeman, T.A., Wickstrom, E., Ducheyne, P., Jungkind, D., Shapiro, I.M., Hickok, N.J.: The inhibition of Staphylococcus epidermidis biofilm formation by vancomycin-modified titanium alloy and implications for the treatment of periprosthetic
53 65 Leclercq, R., Derlot, E., Duval, J., Courvalin, P.: Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium . NEngl J Med 319 , 157
species most frequently isolated from clinical samples ( Maasjost et al., 2009 ) and cloacal samples of poultry ( Ünal et al., 2017; Aslantaş, 2019 ). Glycopeptides (such as vancomycin and teicoplanin) are effective antibiotics for the treatment of Gram
, Werner G: Vancomycin-resistente Enterokokken (VRE). Aktuelle Daten und Trends zur Resistenzentwicklung. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 55, 1387–1400 (2012) Werner G
increased concern and a major pathogen of hospital-acquired infections [ 1, 2 ]. Vancomycin was considered to be the best alternative for the treatment of multidrug-resistant MRSA. However, there have been increasing reports of vancomycin-resistant S
most frequently encountered bacterial species in microbiology laboratories in Nigeria [ 6 , 7 ]. Molecular data on this pathogen in Nigeria is however very limited. As early as 1950, vancomycin, the first glycopeptide antibiotic to be
Hryniewicz, W., Szczypa, K., Bronk, M., Samet, A., Hellmann, A., Trzcinski, K.: First report of vancomycin-resistant Enterococcus faecium isolated in Poland. Clin Microbiol Infect 5 , 503-505 (1999
-type vancomycin-resistant enterococci on Norwegian poultry farms three years after avoparcin was banned. J. Appl. Microbiol. 89 , 478–485. Kruse H. Continuing high prevalence of VanA
References 1. Cetinkaya , Y. , Falk , P. , Mayhall , C.G. : Vancomycin-resistant enterococci . Clin Microbiol Rev 13 , 686 – 707 ( 2000
Cornely, O. A., Crook, D. W., Esposito, R., et al.: Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect. Dis., 2012, 12 , 281